As of June 30, 2026, Vistagen Therapeutics, Inc. carries a market capitalization of 10.03M, placing it among publicly traded companies globally. Its enterprise value stands at -20.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.03M |
| Enterprise Value | -20.92M |
Vistagen Therapeutics, Inc.'s next confirmed earnings release is scheduled for February 11, 2027.
| Earnings Date | 2/11/2027 |
As of June 30, 2026, Vistagen Therapeutics, Inc. has 44.38M shares outstanding.
| Shares Outstanding | 44.38M |
These figures are as of June 30, 2026. The price-to-sales ratio is 3.63, and the price-to-book ratio stands at 0.41.
| PS Ratio | 3.63 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | -0.15 |
| P/OCF Ratio | -0.15 |
As of June 30, 2026, Vistagen Therapeutics, Inc. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.07 |
| Quick Ratio | 2.84 |
| Debt / Equity | 3.20 |
| Debt / EBITDA | -0.01 |
Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. posted a negative return on equity (ROE) of -166.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -129.22, reflecting losses generated across the asset base. The company generates approximately 51,061.22 in revenue per employee across its workforce of 49.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -166.46 |
| Return on Assets (ROA) | -129.22 |
| Revenue Per Employee | 51,061.22 |
| Employee Count | 49.00 |
Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. recorded 7,000.00 in income tax expense. The company reported a pretax loss of -67.61M and -67.62M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 7,000.00 |
As of the close on November 16, 2026, Vistagen Therapeutics, Inc.'s stock has declined approximately 95.15% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.42.
| 52-Week Price Change | -95.15% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.42 |
Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. generated 2.50M in revenue and converted that into -67.62M in net income, yielding earnings per share of -1.68. EBITDA reached -68.90M, while operating income came in at -69.66M.
| Revenue | 2.50M |
| Operating Income | -69.66M |
| Pretax Income | -67.61M |
| Net Income | -67.62M |
| EBITDA | -68.90M |
| EBIT | -69.66M |
| Earnings Per Share (EPS) | -1.68 |
As of June 30, 2026, Vistagen Therapeutics, Inc. holds 31.73M in cash and equivalents against 783,000.00 in total debt, resulting in a net debt position of -16.99M. Total book value stands at 24.48M, with working capital of 23.12M providing operational flexibility.
| Cash & Cash Equivalents | 31.73M |
| Total Debt | 783,000.00 |
| Net Debt | -16.99M |
| Equity (Book Value) | 24.48M |
| Book Value Per Share | 0.55 |
| Working Capital | 23.12M |
Vistagen Therapeutics, Inc. produced -62.30M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -86,000.00 in capital expenditures, free cash flow totaled -62.38M - equivalent to -1.55 per share.
| Operating Cash Flow | -62.30M |
| Capital Expenditures | -86,000.00 |
| Free Cash Flow | -62.38M |
| FCF Per Share | -1.55 |
These figures cover the twelve months ended June 30, 2026. The operating margin of -2,784.33 and net profit margin of -2,702.64 provide insight into operational efficiency.
| Operating Margin | -2,784.33 |
| Pretax Margin | -2,702.36 |
| Profit Margin | -2,702.64 |
| EBITDA Margin | -2,753.92 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -687.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -303.04, meaning Vistagen Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -303.04 |
| FCF Yield | -687.57 |
Vistagen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.
| Last Split Date | 6/7/2023 |
| Split Ratio | 30:1 |
As of June 30, 2026, Vistagen Therapeutics, Inc. has an Altman Z-Score of -24.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.26 |